FDA Grants Inhaled Use IND for RLF-100 (aviptadil) to Treat Patients with Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure
Radnor, PA and Geneva, CH, August 6, 2020– NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF)“Relief” today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Brain | Clinical Trials | COVID-19 | Grants | Investigational New Drugs | Neurology | Pharmaceuticals | Respiratory Medicine